5 November 2024NewsAmericasOlga Zimmerman Director Intellectual Property Caribou Biosciences, Matthew Gordon Vice President Legal Myriad Genetics Inc, Susan Krumplitsch Partner DLA Piper, William Mulholland Partner DLA Piper, Graham Cole Director Intellectual Property Office of Technology Licensing City of Hope

WATCH: Navigating enablement and written description requirement standards in the USPTO

On January 10 this year, the director of the USPTO issued new guidelines on enablement under 35 U.S.C §112. In recent years, the landscape of patent law in the United States has undergone a significant shift, with courts adopting a more stringent stance on the criteria of enablement and written description.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Americas
2 July 2026   A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.
Americas
30 June 2026   Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market.
Americas
25 June 2026   The Federal Circuit has brought Paxlovid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.